Kiora (KPRX) EVP Lane Keith J. Receives Stock Award

What Happened

• Lane Keith J., Executive Vice President, Clinical and Regulatory at Kiora Pharmaceuticals (KPRX), received a grant of a derivative award covering 55,000 shares on September 17, 2026. The filing shows an acquisition amount of $0.00 (this is a grant/option, not a cash purchase or sale).

Key Details

• Transaction date: 2026-09-17. Transaction code: A (award/grant).
• Amount granted: 55,000 shares (derivative instrument / option). Reported acquisition price: $0.00.
• Shares owned after transaction: the filing does not list total beneficial ownership after this grant.
• Vesting (per footnote F1): one-third vests on September 17, 2027; the remaining two-thirds vest monthly on the last day of each calendar month thereafter over two years, subject to continuous service.
• Filing timeliness: reported with the same Period of Report (2026-09-17) — no late filing indicated.
• No 10b5-1 plan, tax withholding, or immediate cashless exercise/sale disclosed in this filing.

Context

• This was an equity compensation grant (an option/derivative), not an immediate stock purchase or sale. The award must vest (and, if it’s an option, be exercised) before shares become sellable; the filing does not detail an exercise price or immediate market value. Equity grants are common executive compensation and do not by themselves indicate immediate buying or selling intent.